Erythromycin
- Generic Name
- Erythromycin
- Brand Names
- Aktipak, Apo-Erythro-S, Benzamycin, E.E.S., Ery, Ery-tab, Erygel, Eryped, Erythro, Erythrocin, Erythrocin Stearate
- Drug Type
- Small Molecule
- Chemical Formula
- C37H67NO13
- CAS Number
- 114-07-8
- Unique Ingredient Identifier
- 63937KV33D
- Background
Erythromycin is a bacteriostatic antibiotic drug produced by a strain of Saccharopolyspora erythraea (formerly Streptomyces erythraeus) and belongs to the macrolide group of antibiotics which consists of Azithromycin, Clarithromycin, Spiramycin and others. It was originally discovered in 1952. Erythromycin is widely used for treating a variety of infections,...
- Indication
Erythromycin is indicated in the treatment of infections caused by susceptible strains of various bacteria. The indications for erythromycin have been summarized by body system below:
Respiratory infections
...
- Associated Conditions
- Acne, Acne Vulgaris, Acute Otitis Media caused by Haemophilus Influenzae, Acute pelvic inflammatory disease caused by Neisseria Gonorrheae Infection, Bacterial Infections, Chancroid, Chlamydia Trachomatis, Chlamydial ophthalmia neonatorum, Community Acquired Pneumonia (CAP), Diphtheria, Erythrasma, Gastroparesis, Granuloma Inguinale, Intestinal amebiasis caused by entamoeba histolytica, Legionella Pneumophila Infections, Listeria infection, Lower Respiratory Tract Infection (LRTI), Lymphogranuloma Venereum, Nongonococcal urethritis, Ophthalmia neonatorum (gonococcal), Pertussis, Postoperative Infections, Primary Syphilis, Respiratory Tract Infections (RTI), Skin and skin structure infections, Staphylococcal Skin Infections, Syphilis, Upper Respiratory Tract Infection, Ureaplasma urethritis, Whooping Cough, Inflammatory papular lesions, Mild Acne vulgaris, Moderate Acne vulgaris, Predominant skin comedones, papules and pustules, Prophylaxis of Rheumatic fever, Pustular lesions, Skin and subcutaneous tissue bacterial infections caused by streptococcus pyogenes, Superficial ocular infections
- Associated Therapies
- -
Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome
- First Posted Date
- 2007-05-01
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- National Human Genome Research Institute (NHGRI)
- Target Recruit Count
- 3
- Registration Number
- NCT00467831
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Use of Erythromycin in Mustard-Induced Bronchiolitis
- Conditions
- First Posted Date
- 2006-08-22
- Last Posted Date
- 2008-11-05
- Lead Sponsor
- Baqiyatallah Medical Sciences University
- Registration Number
- NCT00367419
- Locations
- 🇮🇷
Baqiyatallah Medical Sciences University, Tehran, Iran, Islamic Republic of
The Effect of Concomitant Administration of Erythromycin and Diltiazem on CYP3A Activity in Healthy Volunteers
- First Posted Date
- 2006-04-26
- Last Posted Date
- 2012-04-06
- Lead Sponsor
- Indiana University School of Medicine
- Target Recruit Count
- 7
- Registration Number
- NCT00318201
- Locations
- 🇺🇸
Indiana University Medical Center / GCRC, Indianapolis, Indiana, United States
Effectiveness of Antibiotic Treatment for Reducing Binge Eating and Improving Digestive Function in Bulimia Nervosa
- Conditions
- Interventions
- First Posted Date
- 2006-03-17
- Last Posted Date
- 2018-08-20
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 29
- Registration Number
- NCT00304187
- Locations
- 🇺🇸
Eating Disorders Clinic, New York State Psychiatric Institute, New York, New York, United States
Effects of Long Term Macrolide Antibiotic Therapy in Patients With COPD
- Conditions
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2005-09-07
- Lead Sponsor
- Royal Free and University College Medical School
- Target Recruit Count
- 120
- Registration Number
- NCT00147667
- Locations
- 🇬🇧
Royal Free Hospital, London, England, United Kingdom
Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 3720
- Registration Number
- NCT00021671
- Locations
- 🇺🇸
Megan Valentine, Research Triangle Park, North Carolina, United States
An Open-Label Study in HIV+ Patients to Determine the Effects of Nevirapine (Viramune) on the Pharmacokinetics of Clarithromycin and Activity of Cytochrome 3A4.
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 36
- Registration Number
- NCT00002194
- Locations
- 🇺🇸
South Florida Bioavailability Clinic, Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.